share_log
Reuters ·  Feb 27 12:31
Medicus Pharma Ltd Announces Submission of Phase 2 Clinical Design (Sknjct-004) to United Arab Emirates (UAE) Department of Health (Doh) to Non-Invasively Treat Basal Cell Carcinoma of the Skin (Bcc)
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
Comment Comment · Views 404
Write a comment